Meizu Deepens Its Globalization by Launching Cutting-Edge Smartphones and Wearables

Following its high-profile showcase at MWC 2025 and strategic collaborations with Geely, Meizu reaffirmed its global ambitions with an online launch event on May 20. The event launched five new smartphones-MEIZU Mblu 22, MEIZU Mblu 22 Pro, MEIZU Note 22, MEIZU Note 22 5G, and MEIZU Note 22 Pro 5G-alongside the AR smart glasses StarV […]

Bravo NYC Tours Redefines Exploration with Expert-Led, Intimate NYC Walking Tours

New York, NY – A new player in the city’s competitive tourism landscape, Bravo NYC Tours is making its mark with a fresh approach to NYC walking tours. With a commitment to authenticity, storytelling, and sustainability, the company offers curated experiences led by a guide with deep academic and personal roots in New York City.

“Creative+ Arts Camp 2025” Passing the Torch, Driving Innovation, Cultivating the Next Generation of ‘Arts Ambassadors’

Organised by the Hong Kong Arts Development Council and curated by Youth Square, the “Creative+ Arts Camp 2025” (primary and special schools division), one of the core activities of the 17th Arts Ambassadors-in-School Scheme, was successfully held from 18 to 21 April this year. Over 600 students from the Arts Ambassadors-in-School Scheme took part in

Deca Announces Agreement with IBM to Bring High-Density Fan-Out Interposer Production to North America

TEMPE, Ariz., May 20, 2025 (GLOBE NEWSWIRE) — Deca Technologies today announced the signing of an agreement with IBM to implement Deca's M-Series(TM) and Adaptive Patterning(R) technologies in IBM's advanced packaging facility in Bromont, Quebec. Through the agreement, IBM will implement a high-volume manufacturing line with a focus on Deca's M-Series Fan-out Interposer Technology (MFIT(TM)).

Deca Announces Agreement with IBM to Bring High-Density Fan-Out Interposer Production to North America

Deca Announces Agreement with IBM to Bring High-Density Fan-Out Interposer Production to North America GlobeNewswire May 20, 2025 TEMPE, Ariz., May 20, 2025 (GLOBE NEWSWIRE) — Deca Technologies today announced the signing of an agreement with IBM to implement Deca's M-Series(TM) and Adaptive Patterning(R) technologies in IBM's advanced packaging facility in Bromont, Quebec. Through the

Weibo Announces Results of 2025 Annual General Meeting

Weibo Corporation (“Weibo” or the “Company”) (NASDAQ: WB and HKEX: 9898), a leading social media in China, today announced that the following proposed resolutions submitted for shareholder approval have been adopted at its 2025 annual general meeting of shareholders held today: 1. as an ordinary resolution, THAT Mr. Bo Liu shall be re-elected as a

Hisense and Devialet Redefine Home Entertainment

Hisense, a leading brand in global consumer electronics and home appliances, introduces three new product lines developed in collaboration with French Audio Expert Devialet. Each product will feature the exclusive “Tuned by Devialet” certification, ensuring an optimized sound experience. This strategic partnership highlights Hisense's commitment to delivering top-tier home entertainment by combining Devialet's world-class audio

Tencent Music Entertainment Group to Hold Annual General Meeting on June 27, 2025

Tencent Music Entertainment Group (“TME,” or the “Company”) (NYSE: TME and HKEX: 1698), the leading online music and audio entertainment platform in China, today announced that it will hold its annual general meeting of shareholders (the “AGM”) at 10/F, The Hong Kong Club Building, 3A Chater Road, Central, Hong Kong on Friday, June 27, 2025

Trailhead Biosystems Announces David Llewellyn, PhD, MBA, as Chief Executive Officer

Trailhead Biosystems Inc. (TrailBio.com), a biotechnology company pioneering the creation of iPSC-derived human cells at scale for drug discovery and cell therapy, is pleased to announce the appointment ofDavid Llewellyn, PhD, MBA as its new Chief Executive Officer, and as a member of its Board of Directors. Dr. Llewellyn succeeds Jan Jensen, PhD, who has

Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic

The program, licensed exclusively to BMS, represents the third ADC candidate using the company's proprietary Tubutecan technology to reach the clinic. MUNICH, GERMANY, May 20, 2025 – Tubulis today announced that the first program from its strategic license agreement with Bristol Myers Squibb has entered clinical development, triggering a significant milestone in the ongoing collaboration

Scroll to Top